Latest news with #AFib
Yahoo
21 hours ago
- General
- Yahoo
AFib awareness: Stroke risks & advanced treatment options
PANAMA CITY, Fla. (WMBB) – May is National Stroke Awareness Month, a reminder to stay informed about symptoms and prevention. Atrial fibrillation, or AFib, is a common heart rhythm disorder that is the leading cause of strokes. It creates an irregular heartbeat and increases the risk of blood clots forming in the heart. Those clots can break free, travel to the brain, and cause a stroke. The risk of getting AFib increases with age, but anyone could develop it. Those with AFib are five times more likely to have a stroke and can experience various symptoms. 'Atrial fibrillation can be anywhere from being asymptomatic, meaning having no symptoms at all, to being in the hospital because you feel like you're having a heart attack. Some of these patients describe atrial fibrillation as, 'the big one', where they're sweaty, they're clammy, their chest hurts,' Ascension Bay Medical Center Cardiac Electrophysiologist Dr. Saeed Khaja said. But there are some steps you can take to protect yourself. For example, smartwatches have sensors that monitor heart rate and can detect AFib. Early detection methods like this play a critical role in stroke prevention. 'The sooner you treat them, the more likely that you're going to keep it away and the less likely you're going to have a stroke,' Khaja said. Talk to your doctor for other early detection options. There's no cure for AFib, but there are advanced treatment options available, like pulsed field ablation. 'Pulse field, these electrical impulses that go to the heart that actually inactivate the part of the heart that causes AFib. And the best thing about it is that it does no damage to the tissue around,' Khaja said. 'Gone are the days when you just medicate and you wait till it gets bad. Now you can actually have a patient come to the lab. And I've had young people with their first or second incidence of atrial fibrillation coming to the lab and doing ablation, and now they're off of almost all medications and living a completely normal life, like it never happened.' Ascension Sacred Heart Bay has performed the procedure on 381 patients. For information on stroke warning signs or risk factors, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
22-05-2025
- Business
- Yahoo
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
Bayer AG BAYRY announced that it has initiated a phase I study, which is evaluating its investigational highly selective GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation (AFib). The double-blind, placebo-controlled first-in-human dose escalation study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of BAY 3670549 in healthy participants. AFib is a common heart rhythm disorder that affects around 60 million people across the world. AFib is a notable risk factor for stroke and heart failure. Per management, the current standard for treating acute AFib episodes is electric cardioversion (ECV). However, the process remains challenging as it requires sedation or anesthesia to safely deliver an electrical shock to the patient's heart in order to restore its normal sinus rhythm. BAY 3670549 has the potential to help control the electrical activity of cardiomyocytes in patients with AFib. The successful development of BAY 3670549, should strengthen Bayer's cardiovascular portfolio. Year to date, shares of Bayer have rallied 36.7% against the industry's decline of 3.9%. Image Source: Zacks Investment Research Bayer is making good pipeline progress with some clinical milestones expected later in 2025. Bayer has also made some notable mergers and acquisitions to diversify and boost its portfolio of drug candidates. The company plans to launch new drugs — elinzanetant, a hormone-free treatment for menopause symptoms, and acoramidis, a drug for the treatment of a certain form of heart disease. In February 2025, acoramidis was granted regulatory approval in the EU under the brand name Beyonttra. Bayer had acquired marketing rights to the cardiovascular candidate acoramidis in Europe from BridgeBio BBIO. The rights were acquired from Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V. Bayer has expanded its pipeline in new modalities to include competencies in cell therapy through the acquisition of BlueRock and in gene therapy through the acquisition of AskBio. Bayer, together with its subsidiaries, BlueRock and AskBio, is developing preclinical and clinical cell and gene therapies for treating various disorders, including congestive heart failure and Parkinson's disease, among others. Bayer currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the biotech sector are Halozyme Therapeutics HALO and Amarin Corporation AMRN, each carrying a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for Halozyme's earnings per share have increased from $5.02 to $5.23 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.56 to $6.77. Year to date, shares of HALO have risen 11.8%. HALO's earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.60%. In the past 60 days, estimates for Amarin's loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have increased 14.5%. AMRN's earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 29.11%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report BridgeBio Pharma, Inc. (BBIO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Malaysian Reserve
21-05-2025
- Health
- Malaysian Reserve
OMRON Healthcare Evolves the Blood Pressuring Experience with AI-powered AFib detection
Number one doctor and pharmacist-recommended blood pressure monitor brand introduces blood pressure monitors with OMRON Intellisense™ AFib HOFFMAN ESTATES, Ill., May 21, 2025 /PRNewswire/ — Heralding an evolution of the blood pressure monitoring experience, heart health leader OMRON Healthcare today introduced home blood pressure monitors with built-in AI-powered detection of atrial fibrillation. In a medical device first, OMRON blood pressure monitors which feature the company's new novel machine learning IntelliSense™ AFib algorithm will automatically check for AFib during every blood pressure measurement and can provide early detection for a high stroke1 and heart failure2 risk. 'OMRON Healthcare is evolving the blood pressure monitoring experience by making AFib screening an integral part of every measurement. AFib is a serious condition that is widely undiagnosed. With Intellisense™ AFib, we are working to help anyone who uses our blood pressure monitors detect this condition earlier so they can reduce the associated stroke, heart failure and dementia risks,' said OMRON Healthcare U.S. Managing Director Alice Koehler. OMRON blood pressure monitors with Intellisense™ AFib are compatible with the OMRON Connect app and clinical accurate. OMRON Platinum BP5465: Featuring a backlit dual display and storage for 200 readings for two users (100 readings each user), OMRON Platinum is ranked by The New York Times Wirecutter as the overall 'best blood pressure monitor for home use'. OMRON 10 Series® BP7465: This OMRON best-seller features a large, backlit display with TruRead technology, stores 200 readings for two users (100 readings each user), and is recommended by Consumer Reports for its accuracy and ease of use. OMRON 7 Series® BP7360: With a large, easy-to-read display, this compact monitor stores 120 readings for two users (60 readings each user) and is rated by Health & Living as one of the Best Blood Pressure Monitors of 2025. OMRON Gold BP5360: A favorite for its sleek design and bright display, this monitor stores 160 readings (80 readings per user) and is highly rated as a 'premium option' by BPM Reviews for its exceptional accuracy and ease-of-use. 'Our blood pressure monitors with Intellisense™ AFib automatically screen for atrial fibrillation with every single measurement,' said Koehler. 'With this breakthrough AFib detection, OMRON is setting a new high standard for the blood pressure monitoring experience.' AFib is the most common type of heart arrythmia3. Left untreated, the condition increases risk of stroke, heart failure, myocardial infarction, chronic kidney disease, and dementia4. AFib risk factors accelerate over age 40 and include high blood pressure, obesity, diabetes, smoking, heavy use of alcohol, and sleep apnea5. Medical experts say AFib has become a health epidemic6. A study published in the September 2024 Journal of the American College of Cardiology7 found that AFib is three times more prevalent than previously estimated. The American Stroke Association estimates that millions of Americans with AFib are undiagnosed8 and many may not experience symptoms9. OMRON IntelliSense™ AFib incorporates over 300 mathematical indices into a machine learning algorithm that analyzes the Pressure Pulse Wave generated as the blood pressure monitor cuff inflates. A clinical study published in the October 2024 Heart Rhythm Journal10 found that OMRON blood pressure monitors with Intellisense™ AFib can detect disturbances specific to AFib with remarkable accuracy. The FDA granted OMRON Healthcare medical-device authorization for Intellisense™ AFib via the agency's De Novo classification11, a regulatory pathway for first-of-their-kind innovations.12 With the launch of blood pressure monitors with Intellisense™ AFib, OMRON introduced an AFib education hub that explains the condition, its risk factors, and common symptoms. OMRON's AFib education hub provides details on how Intellisense™ AFib works and how OMRON developed the innovation as part of its Going for Zero mission. AFib education extends to the OMRON Connect app, which syncs with every Intellisense™ AFib blood pressure monitor via Bluetooth to iOS® and Android® devices. OMRON Connect charts user readings by the day, week, month and year. The app analyzes a user's trends and habits, presents insights to explain data, and provides daily reminders and progress reports. With OMRON Connect, a user can send heart health readings to a doctor. 'Research shows ninety percent of heart attacks and strokes are preventable13. By evolving the blood pressure monitoring experience with Intellisense™ AFib, OMRON is providing unprecedented at-home access to technologies that can make a world of difference in heart health,' said Koehler. About OMRON Healthcare, Healthcare, Inc., is the world's leading manufacturer and distributor of personal heart health products and an innovator in technologies supporting respiratory and pain management care. With over 50 years of medical device category leadership, OMRON is passionate about empowering people to take charge of their health at home through precise technology. Its market-leading products include a full range of home blood pressure monitors, nebulizers and TENS devices. The company's mission is Going for Zero, the elimination of heart attacks and strokes. With more than 350 million devices sold globally, OMRON provides the world's most recommended blood pressure monitors by healthcare professionals. OMRON Healthcare strives to improve lives and contribute to a better society by developing innovations that help people prevent, treat, and manage their medical conditions. The company provides products and services in over 130 countries. For more information, visit 1 CDC AFib and Stroke AFib and Heart Failure CDC About Atrial Fibrillation AFib and Dementia Risk NIH AHAIASA Journals JACC study American Stroke Association Cleveland Clinic Heart Rhythm Journal, October 2024 FDA De Novo FDA De Novo AI First Cleveland Clinic
Yahoo
21-05-2025
- Health
- Yahoo
OMRON Healthcare Evolves the Blood Pressuring Experience with AI-powered AFib detection
Number one doctor and pharmacist-recommended blood pressure monitor brand introduces blood pressure monitors with OMRON Intellisense™ AFib HOFFMAN ESTATES, Ill., May 21, 2025 /PRNewswire/ -- Heralding an evolution of the blood pressure monitoring experience, heart health leader OMRON Healthcare today introduced home blood pressure monitors with built-in AI-powered detection of atrial fibrillation. In a medical device first, OMRON blood pressure monitors which feature the company's new novel machine learning IntelliSense™ AFib algorithm will automatically check for AFib during every blood pressure measurement and can provide early detection for a high stroke1 and heart failure2 risk. "OMRON Healthcare is evolving the blood pressure monitoring experience by making AFib screening an integral part of every measurement. AFib is a serious condition that is widely undiagnosed. With Intellisense™ AFib, we are working to help anyone who uses our blood pressure monitors detect this condition earlier so they can reduce the associated stroke, heart failure and dementia risks," said OMRON Healthcare U.S. Managing Director Alice Koehler. OMRON blood pressure monitors with Intellisense™ AFib are compatible with the OMRON Connect app and clinical accurate. OMRON Platinum BP5465: Featuring a backlit dual display and storage for 200 readings for two users (100 readings each user), OMRON Platinum is ranked by The New York Times Wirecutter as the overall "best blood pressure monitor for home use". OMRON 10 Series® BP7465: This OMRON best-seller features a large, backlit display with TruRead technology, stores 200 readings for two users (100 readings each user), and is recommended by Consumer Reports for its accuracy and ease of use. OMRON 7 Series® BP7360: With a large, easy-to-read display, this compact monitor stores 120 readings for two users (60 readings each user) and is rated by Health & Living as one of the Best Blood Pressure Monitors of 2025. OMRON Gold BP5360: A favorite for its sleek design and bright display, this monitor stores 160 readings (80 readings per user) and is highly rated as a "premium option" by BPM Reviews for its exceptional accuracy and ease-of-use. "Our blood pressure monitors with Intellisense™ AFib automatically screen for atrial fibrillation with every single measurement," said Koehler. "With this breakthrough AFib detection, OMRON is setting a new high standard for the blood pressure monitoring experience." AFib is the most common type of heart arrythmia3. Left untreated, the condition increases risk of stroke, heart failure, myocardial infarction, chronic kidney disease, and dementia4. AFib risk factors accelerate over age 40 and include high blood pressure, obesity, diabetes, smoking, heavy use of alcohol, and sleep apnea5. Medical experts say AFib has become a health epidemic6. A study published in the September 2024 Journal of the American College of Cardiology7 found that AFib is three times more prevalent than previously estimated. The American Stroke Association estimates that millions of Americans with AFib are undiagnosed8 and many may not experience symptoms9. OMRON IntelliSense™ AFib incorporates over 300 mathematical indices into a machine learning algorithm that analyzes the Pressure Pulse Wave generated as the blood pressure monitor cuff inflates. A clinical study published in the October 2024 Heart Rhythm Journal10 found that OMRON blood pressure monitors with Intellisense™ AFib can detect disturbances specific to AFib with remarkable accuracy. The FDA granted OMRON Healthcare medical-device authorization for Intellisense™ AFib via the agency's De Novo classification11, a regulatory pathway for first-of-their-kind innovations.12 With the launch of blood pressure monitors with Intellisense™ AFib, OMRON introduced an AFib education hub that explains the condition, its risk factors, and common symptoms. OMRON's AFib education hub provides details on how Intellisense™ AFib works and how OMRON developed the innovation as part of its Going for Zero mission. AFib education extends to the OMRON Connect app, which syncs with every Intellisense™ AFib blood pressure monitor via Bluetooth to iOS® and Android® devices. OMRON Connect charts user readings by the day, week, month and year. The app analyzes a user's trends and habits, presents insights to explain data, and provides daily reminders and progress reports. With OMRON Connect, a user can send heart health readings to a doctor. "Research shows ninety percent of heart attacks and strokes are preventable13. By evolving the blood pressure monitoring experience with Intellisense™ AFib, OMRON is providing unprecedented at-home access to technologies that can make a world of difference in heart health," said Koehler. About OMRON Healthcare, Healthcare, Inc., is the world's leading manufacturer and distributor of personal heart health products and an innovator in technologies supporting respiratory and pain management care. With over 50 years of medical device category leadership, OMRON is passionate about empowering people to take charge of their health at home through precise technology. Its market-leading products include a full range of home blood pressure monitors, nebulizers and TENS devices. The company's mission is Going for Zero, the elimination of heart attacks and strokes. With more than 350 million devices sold globally, OMRON provides the world's most recommended blood pressure monitors by healthcare professionals. OMRON Healthcare strives to improve lives and contribute to a better society by developing innovations that help people prevent, treat, and manage their medical conditions. The company provides products and services in over 130 countries. For more information, visit 1 CDC AFib and Stroke AFib and Heart Failure CDC About Atrial Fibrillation AFib and Dementia Risk NIH AHAIASA Journals JACC study American Stroke Association Cleveland Clinic Heart Rhythm Journal, October 2024 FDA De Novo FDA De Novo AI First Cleveland Clinic View original content to download multimedia: SOURCE OMRON Healthcare Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Epoch Times
15-05-2025
- Health
- Epoch Times
Gum Disease Bacteria Carry Heart Risks, May Trigger Atrial Fibrillation
That nagging bleeding when you brush your teeth may not be just a dental problem—it could be endangering your heart. A new study suggests that the bacterium responsible for gingivitis may slip from infected gums into the bloodstream and infiltrate heart tissue, to increase the risk of irregular heart beats. Irregular heart beats are linked to increased risks of strokes and heart failure. How Gum Disease Attacks Your Heart The findings, recently published in the journal Researchers examined heart tissue from 68 human patients with AFib who had undergone heart surgery and found many of these patients had P. gingivalis in the left atrium of their heart, particularly in the hearts of those with severe gum disease. They also infected mice with P. gingivalis and subsequently found the bacteria inside their hearts as well. These mice were also six times more likely to develop abnormal heart rhythms, such as AFib, compared to mice that were not infected. Researchers pointed out that this study is the first showing clear evidence that P. gingivalis can enter the heart by bacteria leaving the mouth to enter the bloodstream. Related Stories 4/12/2024 2/3/2024 'The causal relationship between periodontitis and atrial fibrillation is still unknown, but the spread of periodontal bacteria through the bloodstream may connect these conditions,' study first author Shunsuke Miyauchi said in a P. gingivalis enters the blood stream via 'periodontal lesions and further translocates to the left atrium [of the heart],' Miyauchi added, noting that the more severe the periodontitis, the more bacteria were found in the heart. Once in the atrium, P. gingivalis can cause scar tissue formation in the heart, which increases the Afib risk, Miyauchi said. Therefore, he noted, periodontal treatment, which can block 'the gateway of P. gingivalis translocation,' may play an important role in AFib prevention and treatment. When the immune system fights gum infections, it releases chemicals that can leak into the blood and cause inflammation all over the body, harming organs including the heart. Harmful bacteria like P. gingivalis have been found in heart tissue, valves, and fatty plaques in arteries. Any bleeding in the gums is an indication of gingivitis, Dr. Jessica Pharar, a dentist and owner of Drs. Chin and Pharar Dentistry in Las Vegas, told The Epoch Times. 'If you see bright red angry looking gums, that is a good indication you are progressing more severe gingivitis,' she added. 'Patients who have other health issues, especially inflammatory diseases, are more prone to gingivitis,' Pharar said. 'Cleaning your mouth twice a day is imperative. Regular check ups at the dentist are essential to protect your overall dental health.' The Wider Impact of Gum Disease The researchers pointed out doctors have noticed for years that people with gum disease frequently have more heart problems and noted that a recent meta-analysis linked gum disease to a 30 percent higher chance of developing AFib. Globally, cases of AFib have 'The prevalence of gum disease continues to be an important public health problem in the United States as 2 in 5 adults are affected by some form of this disease,' Dr. Sandip Sachar, a dentist in New York City, told The Epoch Times. Untreated gum disease can impact overall health beyond just the heart. Pharar cautioned that wherever gingivitis bacteria settles, it can cause problems. Research has consistently linked chronic gum infections to a variety of systemic health Diabetes 'Gum disease and diabetes seem to have a bidirectional relationship,' Sachar said. 'Poor blood sugar control worsens gum disease, and untreated gum disease can increase blood sugar, complicating the overall management of diabetes.' Alzheimer's and Dementia Studies have shown a link between moderate or severe gum disease and an Other Conditions Some studies have linked gum disease to an increased risk of developing certain types of 'Gum disease has also been linked to rheumatoid arthritis, respiratory problems, liver disease, and adverse pregnancy outcomes,' Sachar said. 'Untreated gum disease has been associated with preterm birth and low birth weight. Inflammatory responses in the mouth can potentially affect fetal development.' 'Patients who get a joint replacement can infect their new joint if they don't have good dental health,' Pharar said. However, the condition can be prevented, treated, and even reversed by 'getting professional dental cleanings by a dentist at least twice a year, and maintaining gum health with brushing twice a day, and flossing daily,' Sachar added.
